Ketamine - Dreams and realities

被引:9
作者
Arditti, J [1 ]
Spadari, M [1 ]
de Haro, L [1 ]
Brun, A [1 ]
Bourdon, JH [1 ]
Valli, M [1 ]
机构
[1] Hop Salvator, Toxicol Lab, Ctr Antipoison, F-13009 Marseille, France
来源
ACTA CLINICA BELGICA | 2002年 / 57卷
关键词
D O I
10.1179/acb.2002.073
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Ketamine is an anaesthetic used in human medicine and veterinary practice, synthesised on 1962 and marketed on 1970 in France. Recreational uses were described during 1992 in the medical communauty and in 1996 in the dance settings. The chemical name of ketamine is 2 - (2chlorophenyl)2-(methylamine)-cyclohexanone, an aryl cyclohexylamine, structurally related to phencyclidine. Ketamine is known under the following street names : Keta K, Kate, Special K Vitamine K la Golden, la Veterinaire. Ketamine is used intranasally, orally and intramusculary in recreational use. Ketamine is manufactured by the chemical industry. Due to the complicated synthesis, it is sold illicitly for recreational use. Ketamine is a dissociative drug, and the user enters in a psychedelic dream with hallucinations, floating sensation, feeling of dissociation of the mind from the body. The dream is forgotten, the user fulls in reality with loss of self control, risk of acute intoxication. In long term exposure, tolerance, dependence, withdrawal signs and flash back are described. Ketamine trademarks are subject to control in France through medicine legislation Ketamine and its salts are subject to control under the national legislation on narcotics and psychotropics substance. From September 2001. the theft of medical and veterinary trademarks have to be declared to police, care health authority Pharmacy control authority and French Health Products Safety Agency.
引用
收藏
页码:31 / 33
页数:3
相关论文
共 26 条
[1]   ABUSE OF KETAMINE [J].
AHMED, SN ;
PETCHKOVSKY, L .
BRITISH JOURNAL OF PSYCHIATRY, 1980, 137 (SEP) :303-303
[2]   Swedes alarmed at ketamine misuse [J].
Awuonda, M .
LANCET, 1996, 348 (9020) :122-122
[3]   POSSIBLE ABUSE POTENTIAL OF THE NMDA ANTAGONIST MK-801 [J].
CORBETT, D .
BEHAVIOURAL BRAIN RESEARCH, 1989, 34 (03) :239-246
[4]   Illicit use of ketamine in Scotland [J].
Dalgarno, PJ ;
Shewan, D .
JOURNAL OF PSYCHOACTIVE DRUGS, 1996, 28 (02) :191-199
[5]  
Dillmann J, 1998, Todays Surg Nurse, V20, P37
[6]  
Dillmann J M, 1995, AORN J, V62, P111, DOI 10.1016/S0001-2092(06)63691-0
[7]  
EASTMAN D, 1992, PHARM J, V248, P444
[8]  
FDA, 1979, FDA DRUG B, V9, P24
[9]   DYSTONIC REACTION AFTER KETAMINE ABUSE [J].
FELSER, JM ;
ORBAN, DJ .
ANNALS OF EMERGENCY MEDICINE, 1982, 11 (12) :673-675
[10]  
Gaillard Y, 1998, J FORENSIC SCI, V43, P435